Annexon, Inc. – NASDAQ:ANNX

Annexon stock price today

$2.19
-3.00
-57.8%
Financial Health
0
1
2
3
4
5
6
7
8
9

Annexon stock price monthly change

-14.64%
month

Annexon stock price quarterly change

-14.64%
quarter

Annexon stock price yearly change

+12.10%
year

Annexon key metrics

Market Cap
535.63M
Enterprise value
150.89M
P/E
-1.7
EV/Sales
N/A
EV/EBITDA
-1.10
Price/Sales
N/A
Price/Book
1.11
PEG ratio
-0.07
EPS
-1.47
Revenue
N/A
EBITDA
-129.68M
Income
-120.73M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Annexon stock price history

Annexon stock forecast

Annexon financial statements

Annexon, Inc. (NASDAQ:ANNX): Profit margin
Jun 2023 0 -35.18M
Sep 2023 0 -32.48M
Dec 2023 4.86M -27.89M -573.18%
Mar 2024 0 -25.17M
Annexon, Inc. (NASDAQ:ANNX): Analyst Estimates
Dec 2023 4.86M -27.89M -573.18%
Mar 2024 0 -25.17M
Oct 2025 0 -33.12M
Dec 2025 0 -34.34M
  • Analysts Price target

  • Financials & Ratios estimates

0%
Yield TTM
Annexon, Inc. (NASDAQ:ANNX): Payout ratio
Payout ratio 0%
Annexon, Inc. (NASDAQ:ANNX): Dividend Yield
2019
2020 1.46%
2021
2022
2023
Annexon, Inc. (NASDAQ:ANNX): Debt to assets
Jun 2023 233013000 48.28M 20.72%
Sep 2023 203816000 46.97M 23.05%
Dec 2023 297674000 47.11M 15.83%
Mar 2024 304069000 41.66M 13.7%
Annexon, Inc. (NASDAQ:ANNX): Cash Flow
Jun 2023 -36.38M 5.53M 345K
Sep 2023 -28.29M 47.83M 0
Dec 2023 -23.47M -2.18M 117.59M
Mar 2024 -28.26M -77.30M 32.41M

Annexon alternative data

Annexon, Inc. (NASDAQ:ANNX): Employee count
Aug 2023 80
Sep 2023 77
Oct 2023 77
Nov 2023 77
Dec 2023 76
Jan 2024 76
Feb 2024 76
Mar 2024 71
Apr 2024 71
May 2024 71
Jun 2024 70
Jul 2024 70

Annexon other data

100.00% +0.40%
of ANNX is owned by hedge funds
47.36M +8.94M
shares is hold by hedge funds

Annexon, Inc. (NASDAQ:ANNX): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 17898
Apr 2024 3200 0
May 2024 3200 0
Jun 2024 3200 0
Jul 2024 3200 2994
Aug 2024 3200 5500
Sep 2024 3200 15500
Oct 2024 3200 5408
Dec 2024 3200 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
CARSON WILLIAM H. director
Common Stock 3,200 $5.33 $17,056
Option
LOVE DOUGLAS director, officer.. Common Stock 36,050 $1.85 $66,693
Option
LOVE DOUGLAS director, officer.. Common Stock 78,399 $1.85 $145,038
Option
LOVE DOUGLAS director, officer.. Stock Option (Right to Buy) 36,050 $1.85 $66,693
Option
YEDNOCK TED officer: EVP & CH.. Common Stock 5,408 $1.85 $10,005
Sale
YEDNOCK TED officer: EVP & CH.. Common Stock 5,408 $7.41 $40,073
Option
YEDNOCK TED officer: EVP & CH.. Stock Option (Right to Buy) 5,408 $1.85 $10,005
Purchase
CARSON WILLIAM H. director
Common Stock 3,200 $5.97 $19,104
Sale
YEDNOCK TED officer: EVP & CH.. Common Stock 4,500 $7.1 $31,950
Sale
YEDNOCK TED officer: EVP & CH.. Common Stock 5,500 $6.16 $33,880
Patent
Application
Filling date: 19 Jul 2021 Issue date: 17 Feb 2022
Application
Filling date: 10 Feb 2021 Issue date: 9 Sep 2021
Application
Filling date: 8 Apr 2020 Issue date: 22 Apr 2021
Grant
Filling date: 6 Feb 2020 Issue date: 23 Feb 2021
Application
Filling date: 25 Jun 2020 Issue date: 8 Oct 2020
Application
Filling date: 6 Feb 2020 Issue date: 30 Jul 2020
Grant
Filling date: 23 Nov 2016 Issue date: 28 Jul 2020
Application
Filling date: 1 Nov 2019 Issue date: 7 May 2020
Grant
Filling date: 4 Jan 2019 Issue date: 17 Mar 2020
Application
Filling date: 17 May 2019 Issue date: 17 Oct 2019
Insider Compensation
Mr. Douglas Love J.D., Esq. (1968) Chief Executive Officer, Pres & Director $709,670
Dr. Ted Yednock Ph.D. (1958) Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board $525,430
Mr. Michael Overdorf M.B.A. (1970) Executive Vice President & Chief Bus. Officer
$398,770
Monday, 16 December 2024
globenewswire.com
globenewswire.com
Friday, 15 November 2024
globenewswire.com
Thursday, 14 November 2024
globenewswire.com
Wednesday, 13 November 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Thursday, 3 October 2024
gurufocus.com
Saturday, 17 August 2024
seekingalpha.com
Friday, 16 August 2024
globenewswire.com
Tuesday, 16 July 2024
globenewswire.com
Thursday, 11 July 2024
globenewswire.com
Friday, 28 June 2024
zacks.com
Thursday, 27 June 2024
zacks.com
Tuesday, 25 June 2024
globenewswire.com
Monday, 17 June 2024
globenewswire.com
Friday, 7 June 2024
zacks.com
Wednesday, 5 June 2024
globenewswire.com
zacks.com
zacks.com
Tuesday, 4 June 2024
globenewswire.com
seekingalpha.com
reuters.com
Monday, 3 June 2024
globenewswire.com
Monday, 20 May 2024
zacks.com
Thursday, 16 May 2024
globenewswire.com
Monday, 13 May 2024
globenewswire.com
Thursday, 9 May 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Wednesday, 1 May 2024
globenewswire.com
Thursday, 25 April 2024
zacks.com
  • What's the price of Annexon stock today?

    One share of Annexon stock can currently be purchased for approximately $2.19.

  • When is Annexon's next earnings date?

    Unfortunately, Annexon's (ANNX) next earnings date is currently unknown.

  • Does Annexon pay dividends?

    No, Annexon does not pay dividends.

  • How much money does Annexon make?

    Annexon has a market capitalization of 535.63M.

  • What is Annexon's stock symbol?

    Annexon, Inc. is traded on the NASDAQ under the ticker symbol "ANNX".

  • What is Annexon's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Annexon?

    Shares of Annexon can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Annexon's key executives?

    Annexon's management team includes the following people:

    • Mr. Douglas Love J.D., Esq. Chief Executive Officer, Pres & Director(age: 57, pay: $709,670)
    • Dr. Ted Yednock Ph.D. Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board(age: 67, pay: $525,430)
    • Mr. Michael Overdorf M.B.A. Executive Vice President & Chief Bus. Officer(age: 55, pay: $398,770)
  • How many employees does Annexon have?

    As Jul 2024, Annexon employs 70 workers, which is 1% less then previous quarter.

  • When Annexon went public?

    Annexon, Inc. is publicly traded company for more then 5 years since IPO on 24 Jul 2020.

  • What is Annexon's official website?

    The official website for Annexon is annexonbio.com.

  • Where are Annexon's headquarters?

    Annexon is headquartered at 1400 Sierra Point Parkway, Brisbane, CA.

  • How can i contact Annexon?

    Annexon's mailing address is 1400 Sierra Point Parkway, Brisbane, CA and company can be reached via phone at +65 08225500.

Annexon company profile:

Annexon, Inc.

annexonbio.com
Exchange:

NASDAQ

Full time employees:

71

Industry:

Biotechnology

Sector:

Healthcare

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

1400 Sierra Point Parkway
Brisbane, CA 94005

CIK: 0001528115
ISIN: US03589W1027
CUSIP: 03589W102